UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 7,409	$ 8,414
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation	327	310
Amortization	1,023	3,207
Provision for (recovery of) losses on accounts receivable	(6)	(26)
Amortization of Right of Use Assets	26	26
Deferred income taxes	(364)	(137)
Stock-based compensation expense	131	100
Tax benefit attributable to exercise of stock options	20	9
Changes in operating assets and liabilities
Accounts receivable and other receivables	(297)	2,044
Inventories	441	(1,245)
Prepaid expenses and other current assets	45	3
Accounts payable	66	114
Accrued expenses	(783)	(991)
Total adjustments	629	3,414
Net cash provided by operating activities	8,038	11,828
CASH FLOWS FROM INVESTING ACTIVITIES
Property and equipment	(132)	(363)
Intangible assets	(5)	0
Proceeds from sale of property and equipment	27	0
Net cash used in investing activities	(110)	(363)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock - options	390	81
Common stock purchased and retired	(9,393)	0
Payment of dividends	(2,170)	(2,140)
Net cash used in financing activities	(11,173)	(2,059)
Effect of exchange rate changes on cash	(404)	161
Net increase in cash and cash equivalents	(3,649)	9,567
Cash at beginning of period	92,868	75,052
Cash at end of period	89,219	84,619
Cash paid during the period for income taxes	2,791	2,546
Cash paid during the period for interest	$ 0	$ 0